Can a Veterinary Drug be Repurposed for Human Cancers?: Cytotoxic Effect of Tarantulacubensis Venom on Human Cancer Cells
No Thumbnail Available
Date
2021
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Tarantula cubensis is known as Cuban tarantula having a venom that contains a diversemixture of potent compounds with various biological activities. These peptides have been shown to haveantitumor activities, therefore features of spider-venom peptides prompted scientists to test them as apotential anticancer drug. The purpose of the study was to investigate the potential cytotoxic effect ofTarantula cubensis venom (Logoplex®) on human cancer cells including prostate (PC-3), lung (H69),breast (MDA-MB-231), and ovarian (OVCAR-3). Moreover, non-tumorigenic MCF-10A cells wereused to evaluate the possible cancer cell-specific effect of the extract. The increasing concentrations ofLogoplex® were applied for 24, 48 and 72 h. MTT assay was used to assess cell viability.Concentration-response curves and the IC50 values were determined via Graphpad Prism software.Logoplex® caused a time- and concentration-dependent cytotoxic effect in MDA-MB-231, PC-3,OVCAR-3 and MCF-10A cells and the highest cytotoxicity was achieved at 72h. However, in H69 cells,there was a concentration-dependent cytotoxic effect and the highest cytotoxicity was achieved at 24h.IC50 values of Logoplex® in MDA-MB-231, OVCAR-3, PC-3, H69 and MCF-10A cells weredetermined as 159.3±2.1, 48.9±1.8, 40.2±1.2, 498.3±1.2 and 217.8±2.0 µg/mL, respectively.Logoplex® showed a lower cytotoxic effect against normal cells than the cancer cells suggesting acancer cell-specific effect. According to the preliminary results of this study, although Logoplex® is aveterinary drug, its cytotoxic effect on human cancer cells suggests that it should be re-evaluated as apotential cytotoxic agent. Analyses to identify functional compounds of Tarantula cubensis venom, andfuture studies addressing its mechanism of action on cancer cells are recommended.